2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
09/06/17UroGen Pharma Strengthens Management Team with the Appointment of Paul Chu as Vice President of Business Development
RA'ANANA, Israel, and NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the appointment of Paul Chu to the position of Vice President of Business Development, effective immediately. In this newly-created role, Mr. Chu will be responsible for leading and optimizing the Company’s strategic business development ... 
Printer Friendly Version
09/05/17UroGen Pharma to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
RA'ANANA, Israel, and NEW YORK, Sept. 05, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, the Company’s Chief Executive Officer, will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 at 2:35 p.m. EDT. The conference will be held in New York, NY. A l... 
Printer Friendly Version
08/29/17UroGen Pharma Receives FDA Fast Track Designation for MitoGel™ for the Treatment of Upper Tract Urothelial Carcinoma (UTUC)
RA’ANANA, Israel and NEW YORK, Aug. 29, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s lead product candidate, MitoGel™, for the treatment of patients with low-grade upper tract urothelial carcinoma (UTUC) not amendable to en... 
Printer Friendly Version
08/14/17UroGen Pharma Reports Second Quarter 2017 Financial Results and Recent Corporate Developments
Completed Initial Public Offering Raising $66.9 Million in Gross Proceeds Continuing Enrollment of Patients in the Phase 3 OLYMPUS Clinical Trial of MitoGel™ for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma RA’ANANA, Israel and NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced financial re... 
Printer Friendly Version
07/19/17Investigational New Drug Application for RTGel™ in Combination with BOTOX® for the Treatment of Overactive Bladder Submitted to FDA by Allergan
RA’ANANA, Israel, and NEW YORK, July 19, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it will receive a milestone payment of $7.5 million under its exclusive worldwide licensing agreement with Allergan Pharmaceuticals International Limited, or Allergan, a wholly owned subsidiary of Allergan plc, resulting from Allergan... 
Printer Friendly Version
06/02/17UroGen Pharma to Ring the Nasdaq Stock Market Opening Bell
RA’ANANA, Israel and NEW YORK, June 02, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Arie Belldegrun, MD, UroGen's Chairman, and Ron Bentsur, the Company’s Chief Executive Officer, along with other members of the management team, will ring the Nasdaq stock market opening bell on Thursday, June 8, ... 
Printer Friendly Version
05/30/17UroGen Pharma to Present at the Jefferies 2017 Global Healthcare Conference
RA’ANANA, Israel and NEW YORK, May 30, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, the Company’s Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference on Tuesday, June 6, 2017 at 1:30 p.m. EDT. The conference will be held in New York, NY. A live ... 
Printer Friendly Version
05/16/17UroGen Pharma Appoints Fred E. Cohen, MD, to its Board of Directors
RA’ANANA, Israel and NEW YORK, May 16, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today the appointment of Fred E. Cohen, MD, DPhil, to its Board of Directors. Dr. Cohen will also serve on the Board’s Compensation, Nomination and Governance Committee. Arie Belldegrun, MD, UroGen Pharma’s Chairman, comment... 
Printer Friendly Version
05/11/17UroGen Pharma Announces Two Data Presentations Related to its Clinical Stage Uro-Oncology Candidates at the American Urology Association 2017 Annual Meeting
RA’ANANA, Israel, May 11, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today that the Company has been selected for an oral podium presentation and a poster presentation at the upcoming American Urology Association 2017 Annual Meeting in Boston, Massachusetts from May 12 to May 16, 2017.   The oral podium... 
Printer Friendly Version
05/10/17UroGen Pharma Announces Closing of Initial Public Offering and Exercise of Underwriters’ Option
RA’ANANA, Israel and NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology with a focus on uro-oncology, announced today the closing of its initial public offering on May 9, 2017 of an aggregate of 5,144,378 ordinary shares at a public offering price of $13.00 per share, including the exercise in full of the underwriters’ option to purchas... 
Printer Friendly Version
05/03/17UroGen Pharma Announces Pricing of Initial Public Offering
RA'ANANA, Israel, May 03, 2017 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd., a clinical stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology, announced today the pricing of its initial public offering of 4,473,373 ordinary shares at a public offering price of $13.00 per share for aggregate gross proceeds of approximately $58.2 million. The shares are scheduled to begin trading on The NASDAQ Global Mar... 
Printer Friendly Version
04/24/17UroGen Pharma Welcomes New Board Member Kate Falberg
Ra’anana, Israel, April 24, 2017: UroGen Pharma Ltd., a privately held, clinical stage biopharmaceutical company that is developing advanced non-surgical treatments to address unmet needs in the field of uro-oncology, announced today the appointment of Kathryn “Kate” Falberg to its Board of Directors, effective immediately. Ms. Falberg will also serve as the Chair of the Board’s Audit Committee.Ms. Falberg brings extensive executive leadership and management experience in the life sciences indu... 
Printer Friendly Version
04/03/17UroGen Pharma Announces Enrollment of First Patient in Phase 3 Clinical Trial of MitoGel™ for Treatment of Low-Grade Upper Tract Urothelial Carcinoma
RA'ANANA, Israel and NEW YORK, April 03, 2017 (GLOBE NEWSWIRE) — UroGen Pharma Ltd., a privately held, clinical-stage biopharmaceutical company that is developing advanced non-surgical treatments to address unmet needs in the field of uro-oncology, announced today that the first patient has been enrolled in the OLYMPUS trial, an open-label, single-arm pivotal Phase 3 clinical trial of MitoGel, a novel sustained release formulation of Mitomycin C, for the treatment of non-muscle invasive, l... 
Printer Friendly Version